An interventional study of renal denervation in Treatment Resistant Hypertension and Chronic Hemodialysis, sponsored by University of Erlangen-Nürnberg Medical School. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-09-26.
Sponsored by University of Erlangen-Nürnberg Medical School · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School — 2 open to participants now, 3 under way, none of them phase 3. Hypertension · University of Erlangen-Nürnberg Medical School.
Among the 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School, this one is the 8th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2024, is one of 6 with no phase, and was the 12th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →2 of the 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School are open now, in 1 country. Recruiting first, the newest first:
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75 · Healthy volunteers
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 4 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 28 across the 11 interventional studies, 27 across the 3 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Erlangen-Nürnberg Medical School is the lead sponsor of 277 studies on the registry; 53 are open to participants now.
3 of the studies in Hypertension by University of Erlangen-Nürnberg Medical School that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07359664University of Erlangen-Nürnberg Medical SchoolOCTA in Cardiovascular Disease and Healthy Controls | 2026-12 |
| NCT06556407University of Erlangen-Nürnberg Medical SchoolEffect of Renal Denervation on Bood Pressure in Patients on Hemodialysis | 2026-12-01 |
| NCT07406191University of Erlangen-Nürnberg Medical SchoolWB-EMS Effects on Cardiometabolic Risk Factors | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Hypertension by University of Erlangen-Nürnberg Medical School, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The RDN-HD Study is a prospective, single-center feasibility study. All patients included will undergo endovascular ultrasound-based RDN (no sham group, no blinding). The purpose of the RDN-HD Study is to demonstrate that ultrasound-based RDN is safe in patients with TRH and ESRD hemodialysis and reduces 24-h ambulatory BP.
Patients with end-stage renal disease (ESRD) and hemodialysis have a very high risk for cardiovascular events and a very high cardiovascular mortality. Uncontrolled treatment resistant hypertension (TRH) is an important factor driving this very high cardiovascular event risk. Clinical and experimental studies have clearly shown that sympathetic nerve activity is increased in patients with chronic kidney disease (CKD) and substantially aggravates the progression of CKD. In patients with ESRD and chronic hemodialysis bilateral nephrectomy reduced increased sympathetic nerve activity. Interestingly, kidney transplantation did not normalize peripheral sympathetic activity unless the native kidneys were removed. Thus, afferent sensory nerve signaling from the diseased kidneys to the central nervous system is an important pathophysiologic mechanism in CKD leading to sympathetic overactivity and hypertension. Clinical studies have demonstrated that invasive, catheter-based renal denervation (RDN) decreases the sympathetic nerve activity in the whole body and in particular in the kidneys
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention: Renal denervation
Device: renal denervation
ultrasound based renal denervation
Safety endpoints and adverse effects
A major combined safety endpoint is the incidence of any major adverse events (MAE) through the 6 months FU
Time frame: during 6 months post-procedure
Change in 24-h ambulatory systolic blood pressure between baseline and 3 months post-procedure
Time frame: baseline and 3 months post-procedure
Change in 24-h ambulatory systolic blood pressure between baseline and 6 months post-procedure
Time frame: between baseline and 6 months post-procedure.
Change in 24-h ambulatory diastolic blood pressure between baseline and 3, 6 months post-procedure
Time frame: baseline and 3, 6 months post-procedure.
Change in office (attended) systolic and diastolic blood pressure between baseline and 3, 6 months post-procedure
Time frame: between baseline and 3, 6 months post-procedure
Change in systolic and diastolic home blood pressure between baseline and 3, 6 months post-procedure.
Time frame: between baseline and 3, 6 months post-procedure
Number of antihypertensive drugs, doses, classes at 3, 6 months post-procedure compared to baseline.
Time frame: at 3, 6 months post-procedure compared to baseline.
Change in bio-impedance parameters between baseline and 3, 6 months post-procedure to assess the volume status.
Time frame: between baseline and 3, 6 months post-procedure
Change in central systolic and diastolic blood pressure, central pulse pressure and pulse wave velocity between baseline and 3,6 months post procedure
Time frame: between baseline and 3,6 months post procedure
Change in retinal arteriolar wall to lumen ratio between baseline and 3,6 months post procedure
Time frame: between baseline and 3,6 months post procedure
Change in average daytime/night-time ambulatory systolic blood pressure between baseline and 3, 6 months post-procedure.
Time frame: between baseline and 3, 6 months post-procedure.
Change in average daytime/night-time ambulatory diastolic blood pressure between baseline and 3, 6 months post-procedure
Time frame: between baseline and 3, 6 months post-procedure
Change in office (attended) and ambulatory heart rate between baseline and 3, 6 months post-procedure
Time frame: between baseline and 3, 6 months post-procedure
Changes in dipper/non-dipper patterns between baseline and 3, 6 months post-procedure
Time frame: between baseline and 3, 6 months post-procedure
Change in retinal arterial remodeling between baseline and 3, 6 months post-procedure
Time frame: between baseline and 3, 6 months post-procedure
Change in retinal capillary density between baseline and 3, 6 months post-procedure
Time frame: between baseline and 3, 6 months post-procedure
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 32 months is above that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Erlangen-Nürnberg Medical School →